; and (ii) are not solely drugs that private sector researchers with access to all available information on such drugs chose not to develop. (B) Process The Director shall secure all patent rights to each drug selected under paragraph (1), as applicable, and perform the clinical trials at NIH or subcontract with another entity to conduct the clinical trials. (c) Treatment of approved drugs If a drug for which clinical trials have been conducted by the Center for Clinical Research is approved by the Food and Drug Administration under section 505 of the Federal Food, Drug, and Cosmetic Act or section 351 of this Act, the Director shall— (1) execute non-exclusive licenses to allow drug manufacturers to manufacture and sell the drug; or (2) in collaboration with other Federal agencies as appropriate, enter into purchasing contracts. (d) Public information (1) Research data and findings Subject to applicable patient privacy protections, the Secretary shall— (A) (i) submit all completed studies (and terminated studies, if terminated for safety or ethical reasons) for publication in a peer-reviewed publication within 180 days of completion or termination; and (ii) if a study submitted as described in clause (i) is not selected for publication, publicly disclose all de-identified primary clinical data not later than 180 days after the Secretary's final decision not to pursue further submissions for publication